Biocardia announces timing of the next data safety monitoring board meeting for the cardiamp cell therapy in heart failure pivotal study

Sunnyvale, calif., may 23, 2023 (globe newswire) -- biocardia®, inc.  [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next data safety monitoring board (dsmb) meeting for the cardiamp cell therapy trial for heart failure is scheduled to take place on july 12th. the company expects the fda's response to its adaptive statistical analysis plan supplement early to mid-june and anticipates approval of the plan and completion of all tasks to implement the plan, including all data monitoring, in advance of the dsmb meeting.
BCDA Ratings Summary
BCDA Quant Ranking